Demographic information for cisgender (prepubertal and postpubertal) and transgender healthy control sample donors used for the PBMC and whole blood immunophenotyping cohorts
| PBMC cohort | Prepubertal cis HC | Postpubertal cis HC | Trans HC | P value; (a) prepubertal vs. postpubertal, (b) postpubertal vs. trans |
|---|---|---|---|---|
| Total, n | 26 | 103 | 80 | - |
| Gender identity, F:M | 15:11 | 61:42 | 33:47 | - |
| Mean age, years (range) | 8.5 (6–11) | 19.9 (14–32) | 18.0 (15–19) | (a) N/A (b) 0.0587 |
| Tanner stage 1 (prepuberty) (%) | 26 (100) | 0 (0) | 0 (0) | - |
| Tanner stage 2–3 (in puberty) (%) | 0 (0) | 0 (0) | 2 (2.5) | - |
| Tanner stage 4–5 (completing/completed puberty) (%) | 0 (0) | 103 (100) | 78 (97.5) | - |
| Mean age of menarche, (years) in XX individuals (range) | N/A | 12.5 (9–17) NB data on 58/61 donors | 12.1 (9–14) | (a) N/A (b) 0.2275 |
| Ethnicity (%) | ||||
| Asian (any) | 2 (7.7) | 27 (26.2) | 1 (1.3) | (a) 0.0632 (b) <0.0001 |
| Black (any) | 0 (0) | 9 (8.7) | 1 (1.3) | (a) 0.2027 (b) 0.0445 |
| Other/mixed | 2 (7.7) | 8 (7.8) | 6 (7.5) | (a) >0.9999 (b) >0.9999 |
| White (any) | 22 (84.6) | 59 (57.3) | 72 (90) | (a) 0.0119 (b) <0.0001 |
| Medications | ||||
| Oral contraceptive (%) | 0 (0) | 10 (9.7) | 0 (0) | - |
| GnRHa “blockers” F:M (%) | N/A | N/A | 33:40 (91.3) | - |
| Estradiol (trans-female; oral/patch) (%) | N/A | N/A | 20 (25) | - |
| Testosterone (trans-male; IM) (%) | N/A | N/A | 25 (31.3) | - |
| Mean months on estradiol (trans-female) (range) | N/A | N/A | 13.3 (4.5–23) | - |
| Mean months on testosterone (trans-male) (range) | N/A | N/A | 14.6 (4–43) | |
| Whole blood cohort | 20–40 years | 40–60 years | 60+ years | P value 20–40 vs. 60+ |
| Total, n | 30 | 19 | 25 | - |
| Sex, F:M | 19:11 | 19:0 | 15:10 | >0.9999 |
| Mean age, years (range) | 29.4 (21–40) | 50.6 (43–58) | 68.6 (61–84) | - |
| Asian (%) | 6 (20) | 2 (10.5) | 4 (16) | >0.9999 |
| Black (%) | 0 (0) | 1 (5.3) | 1 (4) | 0.4545 |
| Other/mixed (%) | 2 (6.6) | 0 (0) | 0 (0) | 0.4949 |
| Unknown ethnicity (%) | 3 (10) | 0 (0) | 0 (0) | 0.2424 |
| White (%) | 19 (63.3) | 16 (84.2) | 20 (80) | 0.1569 |
| HRT usage (%) | 0 (0) | 7 (36.8) | 0 (0) | - |
| PBMC cohort | Prepubertal cis HC | Postpubertal cis HC | Trans HC | P value; (a) prepubertal vs. postpubertal, (b) postpubertal vs. trans |
|---|---|---|---|---|
| Total, | 26 | 103 | 80 | - |
| Gender identity, F:M | 15:11 | 61:42 | 33:47 | - |
| Mean age, years (range) | 8.5 (6–11) | 19.9 (14–32) | 18.0 (15–19) | (a) N/A |
| Tanner stage 1 (prepuberty) (%) | 26 (100) | 0 (0) | 0 (0) | - |
| Tanner stage 2–3 (in puberty) (%) | 0 (0) | 0 (0) | 2 (2.5) | - |
| Tanner stage 4–5 (completing/completed puberty) (%) | 0 (0) | 103 (100) | 78 (97.5) | - |
| Mean age of menarche, (years) in XX individuals (range) | N/A | 12.5 (9–17) NB data on 58/61 donors | 12.1 (9–14) | (a) N/A |
| Asian (any) | 2 (7.7) | 27 (26.2) | 1 (1.3) | (a) 0.0632 |
| Black (any) | 0 (0) | 9 (8.7) | 1 (1.3) | (a) 0.2027 |
| Other/mixed | 2 (7.7) | 8 (7.8) | 6 (7.5) | (a) >0.9999 |
| White (any) | 22 (84.6) | 59 (57.3) | 72 (90) | (a) 0.0119 |
| Oral contraceptive (%) | 0 (0) | 10 (9.7) | 0 (0) | - |
| GnRHa “blockers” F:M (%) | N/A | N/A | 33:40 (91.3) | - |
| Estradiol (trans-female; oral/patch) (%) | N/A | N/A | 20 (25) | - |
| Testosterone (trans-male; IM) (%) | N/A | N/A | 25 (31.3) | - |
| Mean months on estradiol (trans-female) (range) | N/A | N/A | 13.3 (4.5–23) | - |
| Mean months on testosterone (trans-male) (range) | N/A | N/A | 14.6 (4–43) | |
| Total, | 30 | 19 | 25 | - |
| Sex, F:M | 19:11 | 19:0 | 15:10 | >0.9999 |
| Mean age, years (range) | 29.4 (21–40) | 50.6 (43–58) | 68.6 (61–84) | - |
| Asian (%) | 6 (20) | 2 (10.5) | 4 (16) | >0.9999 |
| Black (%) | 0 (0) | 1 (5.3) | 1 (4) | 0.4545 |
| Other/mixed (%) | 2 (6.6) | 0 (0) | 0 (0) | 0.4949 |
| Unknown ethnicity (%) | 3 (10) | 0 (0) | 0 (0) | 0.2424 |
| White (%) | 19 (63.3) | 16 (84.2) | 20 (80) | 0.1569 |
| HRT usage (%) | 0 (0) | 7 (36.8) | 0 (0) | - |
HC, healthy control; IM, intramuscular. Fisher’s exact test used to calculate differences between groups.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Please sign in to your personal account to gift article access.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses.
You have reached the limit of 10 links within a 30 day period.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.